HemeOnc

Melanoma

search

Melanoma, Cutaneous Malignant Melanoma, CMM

  • See Also
  1. Ocular Melanoma
  2. Subungual Melanoma
  3. Nevus
  4. Congenital Melanocytic Nevus
  5. Atypical Nevus
  6. Melanoma
  7. Melanoma Risk Factors
  8. Cancer Survivor Care
  • Epidemiology
  1. Deaths: 7700 per year in United States predicted 2005
    1. Sixth leading cause of death in United States
    2. Accounts for 75% of deaths from Skin Cancers
  2. Incidence: 59,580 new U.S. cases estimated for 2005
    1. Accounts for only 3-5% of Skin Cancers
    2. Most common cancer in women age 25 to 29 years (and second most common cancer ages 30-35 years)
  3. Increasing Incidence
    1. Has doubled every 10 years (related to ozone deplete)
    2. One in 74 Americans develop Melanoma yearly
  4. Increasing risk with age
    1. Incidence in age under 14 years: 0.3%
    2. Incidence in age under 20 years: 2%
    3. Median age of diagnosis: 57 years old
    4. Incidence increasing fastest in men over age 65 years
  • Pathophysiology
  1. Melanocyte malignant transformation
  • Risk Factors
  1. See Melanoma Risk Factors
  2. Precursor Lesions
    1. Lentigo maligna
    2. Congenital neoplastic nevi
    3. Clark's melanocytic nevi (Dysplastic Nevus)
  • Classification
  1. Precaution: Melanoma is Melanoma (manage all types aggressively)
  2. Melanoma in Situ
    1. Malignant Melanocytes are confined to the Epidermis
    2. Excision is typically curative with 5 mm margins
  3. Superficial spreading Melanoma (SSM): 70% of Melanoma
    1. More common at age 30-50 years, often on the trunk, and in women often on the legs
    2. Initially brown to black lesions develop blue, red, white color variations
    3. Form irregular, unusual shapes
    4. Initially flat radial growth for months to years and when >2.5 cm vertically grow into Nodules
  4. Nodular Melanoma (NM): 15-20% of Melanoma
    1. More common at age 40-60 years and twice as common in men
    2. No horizontal growth phase and rapid vertical growth over weeks to months
    3. Colors vary from brown or black to red or purple
    4. May appear flesh colored (amelanotic nodular Melanoma) and appear more like Basal Cell Carcinoma
    5. Most frequently misdiagnosed Melanoma (see differential diagnosis below)
  5. Lentigo maligna Melanoma (LMM): 5-15% of Melanoma
    1. More common at age 50-80 years, especially with sun-damaged skin
    2. Develops on the face in 90% of cases
    3. Develops from the precursor lesion Lentigo maligna (Hutchinson's Freckle)
      1. Lentigo maligna is the in situ form of Lentigo maligna Melanoma
      2. Slowly grows over 5 to 15 years prior to shifting into the invasive Lentigo maligna Melanoma
    4. Tumors develop in center of Lentigo maligna
      1. Typically invades after >5 cm in diameter
      2. Invasion can not be determined by external skin exam
  6. Amelanocytic Melanoma: <5% of Melanoma
    1. Nonpigmented Melanoma
    2. Broad differential diagnosis: Eczema, fungal dermatitis, Basal Cell Carcinoma, Squamous Cell Carcinoma
    3. Delay in diagnosis is common and often diagnosed at a more advance stage
  7. Acral Lentiginous Melanoma (ALM): 2-8% of Melanoma
    1. Represents up to 75% of Melanomas in non-caucasian patients (black or asian ethnicity)
    2. Occurs on acral surfaces
      1. Palms, soles, distal digits (knuckles, fingertips), elbows, knees, ears and mucous membranes
    3. Diagnosis often delayed (presenting at more advanced stage with worse outcomes)
      1. Include foot exam with skin exam, especially in non-caucasian patients
  8. Subungual Melanoma: Up to 3.5% of Melanoma
    1. Hutchinson Sign is a pigmented longitudinal band under nail plate (Longitudinal Melanonychia)
    2. Very aggressive tumor with early metastases even from small lesions
    3. Biopsy of lesion including the nail matrix (typically by dermatology)
  • Differential Diagnosis
  1. Melanoma look-alikes in general
    1. Seborrheic Keratosis
    2. Irritated nevus
    3. Pigmented Basal Cell Carcinoma
    4. Lentigo
    5. Blue Nevus
    6. Angiokeratoma (red to blue vascular lesions)
    7. Traumatic Hematoma
    8. Venous lake (Phlebectases: soft, blue purple lesions on face, especially lips and ears)
    9. Hemangioma
    10. Pigmented Actinic Keratosis
  2. Nodular Melanoma
    1. Dermatofibroma (amelanotic)
    2. Basal Cell Cancer (amelanotic)
    3. Hemangioma
    4. Seborrheic Keratosis
    5. Pyogenic Granuloma
  • Lab
  • Histology
  1. Clark's Level
    1. Level 1: Epidermis
    2. Level 2: Reaches papillary Dermis
    3. Level 3: Fills papillary Dermis
    4. Level 4: Enters reticular Dermis
    5. Level 5: Penetrates subcutaneous fat
  2. Five-year survival related to tumor depth
    1. Survival 99%: Depth < 0.85mm
    2. Survival 80%: Depth 0.85 to 1.69mm
    3. Survival 70%: Depth 1.70 to 3.64mm
    4. Survival 40%: Depth > 3.65mm
  • Staging (AJCC)
  1. In-Situ
    1. Stage 0
      1. Confined to Epidermis (99-100% five and ten year survival)
  2. Localized
    1. Stage IA
      1. Thickness <1 mm and not ulcerated
      2. Survival: 97% five year survival and 95% ten year survival
    2. Stage IB
      1. Thickness 1 mm and ulcerated or 1 to 2 mm and not ulcerated
      2. Survival: 92% five year survival and 86% ten year survival
    3. Stage IIA
      1. Thickness 1 to 2 mm and ulcerated or 2 to 4 mm and not ulcerated
      2. Survival: 81% five year survival and 67% ten year survival
    4. Stage IIB
      1. Thickness 2 to 4 mm and ulcerated or >4 mm and not ulcerated
      2. Survival: 70% five year survival and 57% ten year survival
    5. Stage IIC
      1. Thickness >4 mm and ulcerated
      2. Survival: 53% five year survival and 40% ten year survival
  3. Metastatic
    1. Stage III: Regional node metastases
      1. Stage IIIA - Survival: 78% five year survival and 68% ten year survival
      2. Stage IIIB - Survival: 59% five year survival and 43% ten year survival
      3. Stage IIIC - Survival: 40% five year survival and 24% ten year survival
    2. Stage IV: Distant metastases
      1. Survival: 15-20% five year survival and 10-15% ten year survival
  • Evaluation
  • Melanoma metastases
  1. Lymph Node exam
  2. Full skin exam
  3. Chest XRay
  4. Labs considered above stage IA (and in all cases of Stage III and IV)
    1. Complete Blood Count (CBC)
    2. Liver Function Tests (LFT or hepatic panel)
    3. Lactate Dehydrogenase (LDH)
  5. Advanced imaging (indicated for stage III, IV)
    1. CT Head, chest and Abdomen and/or
    2. PET Scan (eyes to thighs)
  • Management
  1. Surgical excision
    1. Local excision with clear margins
      1. Melanoma in situ: Margin 0.5 cm
      2. Breslow thickness <2 mm: Margin 1 cm
      3. Breslow thickness >2 mm: Margin 2 cm
      4. Wide margins (>3 cm) no longer recommended
    2. Lymph Node biopsy indicated if Breslow thickness >1mm
      1. Sentinel Node biopsy for Breslow thickness 1-4 mm
    3. Mohs Micrographic Surgery indicated where surgical margins are difficult to detect
      1. Lentigo maligna
      2. Lentigo maligna Melanoma
  2. Interferon alfa-2b (Intron A)
    1. Effective in increasing relapse-free survival
    2. Wheatley (2003) Cancer Treat Rev 29:241-52 [PubMed]
  • Precautions
  • Defusing Myths
  1. Hairy moles do NOT differentiate benign from malignant
  2. Do not prophylacticly biopsy benign appearing moles
  3. Incisional Biopsy into Melanoma does NOT spread tumor
  • Prevention
  1. See Melanoma Prevention
  2. Follow-up Immediately for:
    1. Pruritic nevus
    2. Atypical Nevus Signs
  3. Frequent skin exams for high risk or Melanoma history
    1. Melanoma in situ (confined to Epidermis)
      1. Follow-up every 6 months for 1 year, then
      2. Follow-up yearly
    2. Stage I: Thickness <1 mm and no Atypical Nevus syndrome or FHx
      1. Follow-up every 3-4 months for year 1, then
      2. Follow-up every 6 months for year 2, then
      3. Follow-up yearly
    3. Stage II: Thickness >1 mm or Clark's Level IV
      1. CBC, chemistry panel, LDH every 6 months
      2. Consider Chest XRay
      3. Follow up every 3-4 months for first 3 years, then
      4. Follow up every 6 months for next 2 years, then
      5. Follow-up annually
    4. Stage III: Regional Metastases
      1. CBC, chemistry panel, LDH every 3-6 months
      2. PET Scan and/or CT Scan (per oncology recommendations)
      3. Follow up every 3-6 months for first 3 years, then
      4. Follow up every 4-12 months for next 2 years, then
      5. Follow-up annually
    5. Stage IV: Distant Metastases
      1. Chest XRay, CBC, Liver Function Tests every 3 months
      2. PET Scan and/or CT Scan every 2-4 months for first 5 years and then annually
      3. Follow-up every 3-4 months
  • Prognosis
  1. See Histology and Staging above
  2. Survival rates are better in women
  3. Relative Risk of developing a second primary tumor: 10
    1. Second primary cancer develops in 4-8% of Melanoma survivors
    2. Melanoma recurrence may occur more than 10-20 years after the initial Melanoma management
  • References
  1. Fauci (1998) Harrison's Medicine, 14th ed., McGraw-Hill
  2. Goldstein (2001) Am Fam Physician 63(7): 1359-68 [PubMed]
  3. Houghton (1998) Oncology 12:153-77 [PubMed]
  4. Landis (1999) CA Cancer J Clin 49:8-31 [PubMed]
  5. Rager (2005) Am Fam Physician 72:269-76 [PubMed]
  6. Shenenberger (2012) Am Fam Physician 85(2): 161-8 [PubMed]
  7. Wilbur (2014) Am Fam Physician 91(1):29-36 [PubMed]